Patients type | BTK inhibitor regimens | Efficacy | Study | Phase | N |
---|---|---|---|---|---|
Patients with R/R MZL | Zanubrutinib | ORR: 68.2%; CR rate: 25.8%; median PFS: NR | MAGNOLIA [126] | 2 | 68 |
Acalabrutinib | ORR: 53%; CR rate: 13%; median PFS: 27.4Â months | ACE-LY-003 [127] | 1/2 | 43 | |
Ibrutinib | ORR: 58%; CR rate: 10%; median PFS: 15.7Â months | PCYC-1121 [128] | 2 | 63 |